Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcutis Biotherapeutics Inc ARQT

Healthcare Biotechnology
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment... see more

Recent & Breaking News (NDAQ:ARQT)

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

GlobeNewswire March 28, 2022

Arcutis' Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study

GlobeNewswire March 25, 2022

Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting

GlobeNewswire March 25, 2022

National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments

GlobeNewswire March 22, 2022

Arcutis to Host Investor Day on March 28

GlobeNewswire March 21, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 14, 2022

Arcutis to Present at Upcoming Investor Conference

GlobeNewswire March 2, 2022

Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire February 22, 2022

Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis

GlobeNewswire February 1, 2022

Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners

GlobeNewswire December 23, 2021

FDA Accepts Arcutis Biotherapeutics' New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

GlobeNewswire December 22, 2021

Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

GlobeNewswire December 16, 2021

Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream

GlobeNewswire December 13, 2021

Arcutis to Present at Upcoming Investor Conference

GlobeNewswire November 10, 2021

Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 4, 2021

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

GlobeNewswire October 4, 2021

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress

GlobeNewswire September 30, 2021

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

GlobeNewswire September 28, 2021

New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress

GlobeNewswire September 27, 2021

Arcutis to Present at Upcoming Investor Conferences

GlobeNewswire September 9, 2021